Idecabtagene Vicleucel in Adults Aged 65 Years and Older
July 14, 2025 • CAR-T Content Hub
Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from a recent study of real-world outcomes among patients aged 65 years and older with multiple myeloma who received idecabtagene vicleucel treatment. This study demonstrated that older patients can safely receive idecabtagene vicleucel CAR T-cell therapy, even if they were also on multiple other medications as a result of various comorbidities. Furthermore, idecabtagene vicleucel led to significantly improved quality of life.
